Brooklyn ImmunoTherapeutics (NYSEMKT: BTX), a relative newcomer to the world of publicly traded biotech stocks, saw its shares rip higher in April by a stunning 1,230%, according to data provided by S&P Global Market Intelligence. In late April, Brooklyn secured an exclusive license for mRNA gene-editing and cell-therapies technology from Factor Bioscience and Novellus Therapeutics. This novel therapeutic platform has attracted significant interest from investors since the rapid development of mRNA-based COVID-19 vaccines from both Moderna and Pfizer/BioNTech.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting